Which population groups should be targeted for cardiovascular prevention? A modelling study based on the Norwegian Hordaland Health Study (HUSK)

Scandinavian Journal of Primary Health Care

Volumn 25, Issue 2, 2007, Pages 105-111

  Brekke, Mette ^a   Rekdal, Magne ^b,c   Straand, Jørund ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b Emetra AS   (Norway)

^c Norwegian EHR Research Centre   (Norway)

Author keywords

Cardiovascular disease; Family practice; Guidelines; Modelling study; Risk

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NORWAY; PATIENT SELECTION; POPULATION RESEARCH; PRACTICE GUIDELINE; RISK FACTOR; SMOKING;

ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; NORWAY; PRACTICE GUIDELINES; PRIMARY PREVENTION; QUESTIONNAIRES; RISK FACTORS;

EID: 34248589849     PISSN: 02813432     EISSN: 15027724     Source Type: Journal    
DOI: 10.1080/02813430701241087     Document Type: Article

References (35)

1. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14:32-8.
2. Jackson R, Harper S. Preventing coronary heart disease. BMJ 2006;332:617-8.
3. Manuel D, Lim J, Tanuseputro P, Anderson GM, Alter DA, Laupacis A, et al. Revisiting Rose: Strategies for reducing coronary heart disease. BMJ 2006;332:359-62.
4. Wald N, Law M. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
5. De Backer G, Amrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. Third Joint Task Force in European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601-10.
6. Mosca L, Apple LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, et al. Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol 2004;900-21.
7. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002;105:310-5.
8. Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
9. New Zealand Guideline Group. Assessment and management of cardiovascular risk 2003. Available at: http://www.nzgg.org.nz/ (accessed 22 April 2006).
10. Getz L, Sigurdsson JA, Hetlevik I, Kirkengen AL, Romundstad S, Holmen J. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: Modelling study. BMJ 2005. doi:10.1136/bmj.38555.648623.8F (published 15 August 2005).
11. Hartz I, Njølstad I, Eggen AE. Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001. Eur Heart J 2005;26:2673-80.
12. Philips L, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Clinical inertia. Ann Intern Med 2001;135:825-34.
13. Westin S, Heath I. Thresholds for normal blood-pressure and serum cholesterol. BMJ 2005;330:1461-2.
14. Getz L, Kirkengen AL, Hetlevik I, Sigurdsson JA. Individually based preventive medical recommendations - are they sustainable and responsible? Scand J Prim Health Care 2005;23:65-7.
15. University of Bergen. Helseundersøkelsen i Hordaland. Available at: http://www.uib.no/isf/husk (accessed 29 June 2006).
16. Anderson K, Wilson PWF, Odell PM. An updated coronary risk profile: A statement for health professionals. Circulation 1991;83:356-62.
17. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: Prospective cohort study. BMJ 2003;327:1267.
18. Conroy R, Pyörälä K, Fitzgerald AP, Sans S, De Backer G, De Bacquer P, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24:987-1003.
19. Soegaard A, Selmer R, Bjertness E, Thelle D. The Oslo Health Study: The impact of self-selection in a large, population based survey. Int J Equity Health 2004;3:1-28.
20. Available at: http://www.uib.no/isf/husk/Vedlegg dokumenter/ FrafallsanalyseHUSK9799 (accessed 29 September 2006)
21. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonen H, Ruokokoski E, Amoyel P. Contributions of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. Lancet 1999;353:1547-57.
22. Hunink M, Goldman KL, Tosteson A, Mittleman M, Goldman P, Williams L. The recent decline in mortality from CHD, 1980-1990. JAMA 1997;277:535-42.
23. Unal B, Alison J, Critchley A, Capewell A. Modeling the decline in coronary heart disease deaths in England and Wales, 1980-2000: Comparing contribution from primary prevention and secondary prevention. BMJ 2005;331:614-7.
24. Tunstall-Pedoe H, Connaghan J, Woodward M, Tolonen H, Kuulasmaa K. Pattern of declining blood pressure across replicate population surveys of the WHO MONICA project, mid-1980s to mid-1990s, and the role of medication. BMJ 2006;332:629-32.
25. Bjartveit K, Stensvold I, Lund-Larsen PG, Graff-Iversen S. Cardiovascular disease prevention programmes in Norwegian counties (English summary). Tidsskr Nor Lægeforen 1991;111:2072-6.
26. Wøien G, Øyen O, Graff-Iversen S. 22 years of cardiovascular surveys in Norwegian counties: Is the development in risk factors satisfactory? (English summary). Nor J Epidemiol 1997;7:255-66.
27. Lloyd-Jones DM, Tian L. Predicting cardiovascular risk. So what do we do now? Arch Intern Med 2006;166:1342-4.
28. Manuel DG, Kwong K, Tanuseputro P, Lim J, Mustard CA, Anderson GM, et al. Effectiveness and efficiency of different guidelines on statin treatment for preventing deaths from coronary heart disease: Modelling study. BMJ 2006;332:1419-22.
29. Walley T, Follino-Gallo P, Schwabe U, van Ganse E, on behalf of the EutoMedStat Group. Variations and increase in use of statins across Europe: Data from administrative databases. BMJ 2004;328:385-6.
30. Hartz I, Njølstad I, Furu K, Skurtveit S, Eggen AE. Why do sales of lipid-lowering drugs vary between counties in Norway? Scand J Prim Health Care 2006;24:115-21.
31. Hartz I, Eggen AE, Grimsgaard S, Skjold F, Njølstad I. Whom are we treating with lipid-lowering drugs? Are we following the guidelines? Evidence from a population-based study: The Tromsø Study 2001. Eur J Clin Pharmacol 2004;60:643-9.
32. Tonstad S, Rosvold E, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med 2004;255:494-502.
33. Rønning M. Drug consumption in Norway 1998-2003. Oslo: WHO Collaborating Centre for Drug Statistics and Methdology; 2003.
34. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80(Suppl 2):1-29.
35. Treatment and prevention of coronary heart disease by cholesterol lowering therapy: Consensus cholesterol, second revision (in Dutch). Utrecht: CBO; 1998.